Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1447970
This article is part of the Research Topic Targeting the Tumor Microenvironment for Effective Treatment of Gastrointestinal Cancers View all 4 articles

Unraveling the regulatory cell death pathways in gastric cancer: A multi-omics study

Provisionally accepted
Jiazheng Sun Jiazheng Sun 1Lixiang Rao Lixiang Rao 1*Sirui Zhou Sirui Zhou 1Yulan Zeng Yulan Zeng 1*Yalu Sun Yalu Sun 2*
  • 1 Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 2 Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China

The final, formatted version of the article will be published soon.

    Gastric cancer (GC) is a prevalent form of cancer worldwide and has a high death rate, with less than 40% of patients surviving for 5 years. GC demonstrates a vital characteristic of evading regulatory cell death (RCD). However, the extent to which RCD patterns are clinically significant in GC has not been well investigated. The study created a regulatory cell death index (RCDI) signature by employing 101 machine-learning algorithms. These algorithms were based on the expression files of 1292 GC patients from 6 multicenter cohorts.RCDI is a reliable and robust determinant of the likelihood of surviving in general.Furthermore, the precision of RCDI surpasses that of the 20 signatures that have been previously disclosed. The presence of RCDI signature is closely linked to immunological characteristics, such as the infiltration of immune cells, the presence of immunotherapy markers, and the activation of immune-related functions. This suggests that there is a higher level of immune activity in cases with RCDI signature. Collectively, the use of RCDI has the potential to be a strong and encouraging method for enhancing the clinical results of individual individuals with GC.

    Keywords: gastric cancer, Regulatory cell death, immune microenvironment, Prognostic signature, Immunotherapy

    Received: 12 Jun 2024; Accepted: 26 Aug 2024.

    Copyright: © 2024 Sun, Rao, Zhou, Zeng and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Lixiang Rao, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Yulan Zeng, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Yalu Sun, Affiliated Hospital of Jining Medical University, Jining, 272000, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.